Our Pricing

Buy Eropid Online UK Pharmacy

Published on: June 03, 2026

If you're looking to buy Eropid online UK pharmacy services, it's important to understand your weight loss treatment options available through registered UK pharmacies. At Cured Pharmacy, our UK-registered clinical team provides free online consultations for evidence-based weight loss medications, all dispensed with complete discretion and regulatory compliance.

Understanding Weight Loss Treatment Options in the UK

The UK weight loss medication landscape has evolved significantly, with several MHRA-licensed treatments now available through registered online pharmacies. Modern weight loss medications work through different mechanisms, from GLP-1 receptor agonists that regulate appetite hormones to lipase inhibitors that reduce fat absorption [1].

Clinical evidence demonstrates that prescription weight loss medications, when combined with lifestyle modifications, can help patients achieve meaningful weight reduction. The STEP trials showed that GLP-1 treatments produced average weight loss of 15-20% over 68 weeks, whilst orlistat-based therapies typically support more modest reductions of 5-10% [1][2].

All prescription weight loss medications available through Cured Pharmacy require clinical assessment by a UK-registered prescriber. Our online consultation process takes under three minutes and ensures each treatment is appropriate for your individual circumstances, medical history, and weight loss goals.

GLP-1 Weight Loss Injections: Mounjaro, Wegovy, and Saxenda

GLP-1 receptor agonists represent the most effective class of weight loss medication currently licensed in the UK. These injectable treatments mimic natural hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity [3].

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist, activating two complementary pathways rather than one. In the SURPASS-3 trial, participants achieved average weight reduction of 22.5% over 72 weeks on the highest dose — significantly exceeding results from single-pathway alternatives [3][4]. Mounjaro is administered once weekly and starts from £135.00 at Cured Pharmacy, subject to prescriber approval.

Wegovy contains semaglutide, a selective GLP-1 receptor agonist that demonstrated average weight loss of 15.3% in the STEP-1 trial over 68 weeks [2]. Administered once weekly, Wegovy offers a well-established safety profile and is available from competitive UK pricing. Saxenda uses liraglutide, an earlier-generation GLP-1 medication requiring daily injection, which may suit patients preferring shorter-acting formulations.

Which GLP-1 Treatment Is Right for You?

Your UK prescriber will assess multiple factors including your BMI, medical history, previous weight loss attempts, and any contraindications. Patients with type 2 diabetes may particularly benefit from tirzepatide's dual mechanism, whilst those preferring daily control might opt for Saxenda. All three medications require ongoing monitoring and lifestyle modification for optimal results.

Orlistat-Based Weight Loss Treatments

Orlistat works through a completely different mechanism than GLP-1 medications, inhibiting pancreatic lipase enzymes to prevent approximately 30% of dietary fat absorption [5]. This non-systemic approach means orlistat remains in the digestive tract rather than entering the bloodstream, offering a distinct safety profile.

Available in both 120mg prescription strength (Orlistat, Xenical) and 60mg over-the-counter formulations (Alli, Orlos), orlistat-based treatments suit patients who prefer oral capsules over injections. Clinical trials demonstrate average weight loss of 5-10% when combined with a reduced-calorie diet, with gastrointestinal side effects manageable through dietary fat restriction [5][6].

Orlos represents the most accessible entry point for orlistat therapy, whilst Xenical provides the branded 120mg formulation. All orlistat products require commitment to a lower-fat diet (less than 30% calories from fat) to minimise side effects and maximise efficacy. Our clinical team can guide you through dietary adjustments during your consultation.

Managing Orlistat Side Effects

The most common side effects relate to unabsorbed fat passing through the digestive system, including oily stools, increased bowel movements, and flatulence. These effects typically diminish as patients adapt their fat intake and are significantly reduced when dietary fat remains below recommended thresholds. Taking a multivitamin supplement at bedtime is advised, as orlistat may reduce absorption of fat-soluble vitamins [5].

Mysimba: Combination Therapy for Weight Management

Mysimba combines naltrexone (an opioid antagonist) with bupropion (a norepinephrine and dopamine reuptake inhibitor) to target the central nervous system's reward and appetite centres [7]. This dual-action oral tablet offers an alternative mechanism for patients who may not be suitable candidates for GLP-1 injections or orlistat.

Clinical trials showed Mysimba produced average weight loss of 5-10% over 56 weeks when combined with lifestyle intervention, with particular efficacy in patients with binge-eating tendencies [7]. The medication requires gradual dose escalation over four weeks to minimise side effects including nausea, headache, and constipation.

Mysimba is contraindicated in patients with uncontrolled hypertension, seizure disorders, or those taking certain medications including MAO inhibitors and opioid painkillers. Your UK prescriber will conduct thorough screening during your online consultation to ensure Mysimba is safe and appropriate for your circumstances.

How to Buy Weight Loss Medication Through Cured Pharmacy

Our streamlined process ensures you can access prescription weight loss treatments quickly and discreetly. Begin by completing our free online consultation, which takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications.

A UK-registered prescriber reviews your consultation within hours, assessing whether prescription weight loss medication is clinically appropriate. If approved, your medication is dispensed by our GPhC-registered pharmacy (registration number 9012511) and dispatched in completely discreet packaging with next-day delivery options available.

All pricing is transparent and displayed upfront before you complete your consultation — no hidden fees or surprise charges. We guarantee the lowest prices in the UK for genuine, licensed medications, with ongoing support from our clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Ongoing Support and Monitoring

Weight loss medication works best as part of a comprehensive approach including dietary modification, increased physical activity, and behavioural changes. Our clinical team provides guidance on lifestyle adjustments, managing side effects, and optimising your treatment regimen. Regular follow-up consultations ensure your medication remains appropriate and effective as you progress towards your weight loss goals.

Safety Considerations and Clinical Guidance

All prescription weight loss medications carry specific contraindications and require careful patient selection. GLP-1 treatments are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [3]. Orlistat should be avoided in patients with chronic malabsorption syndrome or cholestasis [5].

Common side effects vary by medication class. GLP-1 agonists typically cause gastrointestinal symptoms including nausea, vomiting, and diarrhoea, usually diminishing over the first 4-8 weeks [3]. Orlistat's effects relate to fat malabsorption, whilst Mysimba may cause neuropsychiatric symptoms requiring monitoring [7].

Pregnancy and breastfeeding are contraindications for all weight loss medications discussed. Women of childbearing potential should use reliable contraception during treatment with GLP-1 medications, as significant weight loss may increase fertility. Always disclose all current medications during your consultation, as drug interactions may affect suitability or require dose adjustments.

The MHRA and NICE provide ongoing guidance on weight loss medication use in the UK. Our prescribing protocols align with current clinical guidelines, ensuring you receive evidence-based treatment appropriate for your individual circumstances. Never purchase weight loss medication from unregistered sources, as counterfeit products pose serious health risks.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Ludvik, B., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
5. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Sjöström, L., et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet, 352(9123), 167–172. https://doi.org/10.1016/S0140-6736(97)11509-4 [accessed 13 August 2026]
7. Greenway, F. L., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.